A phase 2 study of tislelizumab combined with bevacizumab and chemotherapy as first-line treatment for persistent, recurrent, or metastatic cervical cancer
This work was supported by grants from the Pioneer R&D Program of Zhejiang (2023SDYXS0001, 2022C03031) and by BeiGene (Beijing) Co., Ltd. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Authors
- Jianqing Zhu (ORCID: https://orcid.org/0000-0001-5736-7397)
- Yuhua Gao (ORCID: https://orcid.org/0000-0002-5462-2951)
- Shuhuai Niu
- Hongqin Zhao (ORCID: https://orcid.org/0000-0003-3960-2941)
- Qiang Wen (ORCID: https://orcid.org/0000-0003-3303-3389)
- Hao Yu (ORCID: https://orcid.org/0000-0002-9910-7312)
- Hongtu Chao
- Mei Pan (ORCID: https://orcid.org/0009-0004-4277-0609)
- Youguo Chen (ORCID: https://orcid.org/0000-0002-4162-0324)
Institutions
- Hebei Medical University (CN)
- Wenzhou Medical University (CN)
- First Affiliated Hospital of Wenzhou Medical University (CN)
- Soochow University (CN)
- Zhejiang Cancer Hospital (CN)
- Fourth Hospital of Hebei Medical University (CN)
- Jiangxi Maternal and Child Health Hospital (CN)
- Hangzhou Academy of Agricultural Sciences (CN)
- Henan Cancer Hospital (CN)
- First Affiliated Hospital of Soochow University (CN)
- Liaoning Cancer Hospital & Institute (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- EClinicalMedicine
- Published
- 2025-06-24
- DOI
- https://doi.org/10.1016/j.eclinm.2025.103308
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- BeiGene